Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy.
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer / Mines, F., Caffo, O., Veccia, A., Trentin, C., Tortora, G., Galligioni, E., Bria, E.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 96:3(2015), pp. 498-506. [10.1016/j.critrevonc.2015.07.013]
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
Caffo, Orazio
;Veccia, Antonello;
2015-01-01
Abstract
Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1040842815300135-main.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
955.31 kB
Formato
Adobe PDF
|
955.31 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
